Aditxt Inc
ADTX
查看详细走势图
0.651USD
+0.032+5.20%
收盘 02/06, 16:00（美东）报价延迟15分钟
293.60总市值
0.00市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.20%
5天
-20.25%
1月
-22.54%
6月
-99.53%
今年开始到现在
-21.99%
1年
-99.97%
查看详细走势图
TradingKey Aditxt Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Aditxt Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名239/392位。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aditxt Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Aditxt Inc亮点
亮点风险
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
业绩增长期
公司处于发展阶段，最新年度总收入133.99K美元
利润高增长
公司净利润处于行业前列，最新年度总收入133.99K美元
估值合理
公司最新PE估值0.00，处于3年历史合理位
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aditxt Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aditxt Inc简介
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
公司代码ADTX
公司Aditxt Inc
CEOAlbanna (Amro A)
网址https://aditxt.com/
